

From: [REDACTED] [REDACTED]  
Sent: 20 March 2009 15:23  
To: David Bevan  
Subject: RE: Myelodysplastic syndrome - azacitidine - RCN Response

Importance: High

Follow Up Flag: Follow up  
Flag Status: Flagged

Dear David

Nurses working in this area of health have considered the invitation to submit a professional statement to inform this technology appraisal at this stage. The Royal College of Nursing will participate in the next stage of the appraisal.

Thank you for the invitation.

Please acknowledge receipt.

Regards

[REDACTED]

[REDACTED]

20 Cavendish Square  
London  
W1G 0RN

Tel: [REDACTED]  
Fax: [REDACTED]

-----  
<http://www.rcn.org.uk>

This email is confidential and intended solely for the use of the individual to whom it is addressed. Any views or opinions presented are solely those of the author and do not necessarily represent those of the Royal College of Nursing or any of its affiliates.

If you are not the intended recipient be advised that you have received this email in error and that any use, dissemination, forwarding, printing or copying of this email is strictly prohibited. If you have received this email in error please return it to the sender immediately. The contents of this message may be legally privileged.

Royal College of Nursing of the United Kingdom  
20 Cavendish Square  
London W1G 0RN

Registered Charity Number: 276435

Tel: +44 (0) 845 456 3996

Fax: +44 (0) 20 7647 3436

---

Delivered via MessageLabs

---